HeartSciences Inc. (HSCS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $10.56M
Last updated: Nov 17, 2026 at 11:01 AM ET
HeartSciences Inc. (HSCS) Financials: Revenue, Profit and Cash Flow
HeartSciences reported revenue of $4.32K for the fiscal year ended Apr 30, 2026, down 0.7% from the year before. That year, net income was -$9.14M with a net margin of -211666.5%, operating cash flow was -$7.43M and free cash flow was -$7.43M. The quarter ended Jul 31, 2026 had revenue of $2.10K and net income of -$3.17M.
Revenue and Margins
Over the 6 years to Apr 2026, revenue fell from $64.18K, a compound annual decline of 36.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Apr 2026 | $4.32K | -0.7% | 59.1% | -194787.4% | -211666.5% |
| Apr 2025 | $4.35K | -76.6% | 56.8% | -192013.1% | -201499.5% |
| Apr 2024 | $18.60K | +261.2% | 67.3% | -33902.0% | -35511.9% |
| Apr 2023 | $5.15K | -64.2% | 45.7% | -118698.3% | -123384.3% |
| Apr 2022 | $14.37K | -43.9% | 45.1% | -32765.6% | -33592.6% |
| Apr 2021 | $25.60K | -60.1% | -72.9% | -10030.2% | -9577.3% |
| Apr 2020 | $64.18K | N/A | -71.8% | -5949.0% | -5938.0% |
Income Statement
In the fiscal year ended Apr 2026, the net loss widened from the year before. In the quarter ended Jul 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.32K | $4.35K | $18.60K | $5.15K | $14.37K | $25.60K | $64.18K |
| Cost of revenue | $1.77K | $1.88K | $6.08K | $2.80K | $7.89K | $44.28K | $110.29K |
| Gross profit | $2.55K | $2.47K | $12.52K | $2.35K | $6.48K | -$18.67K | -$46.10K |
| Research and development | $2.84M | $4.39M | $2.88M | $2.46M | $3.00M | $1.71M | $2.04M |
| Operating income | -$8.41M | -$8.35M | -$6.31M | -$6.11M | -$4.71M | -$2.57M | -$3.82M |
| Net income | -$9.14M | -$8.77M | -$6.61M | -$6.35M | -$4.83M | -$2.45M | -$3.81M |
| EBITDA | -$7.76M | -$7.85M | -$6.05M | -$6.02M | -$4.52M | -$2.29M | -$3.74M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.10K | $89.49M | $0 | $2.42K | $1.90K | $31 | $0 | $0 | $0 | $0 | $14.70K | $3.90K |
| Gross profit | $1.34K | $29.11M | $0 | $1.41K | $1.14K | -$81 | $0 | $0 | $0 | -$9.20K | $10.14K | $2.38K |
| Operating income | -$2.94M | -$10.55M | -$1.93M | -$2.07M | -$1.87M | -$2.03M | -$2.37M | -$1.99M | -$2.08M | -$1.88M | -$1.53M | -$1.57M |
| Net income | -$3.17M | -$6.29M | -$1.99M | -$2.35M | -$2.05M | -$1.82M | -$2.54M | -$2.08M | -$2.05M | -$1.85M | -$1.64M | -$1.75M |
Balance Sheet
As of Jun 2026, short-term debt of $3.62M exceeded cash and equivalents by $1.97M.
Annual
| Line item | Jun 2026 | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.26M | $5.26M | $4.22M | $9.50M | $3.29M | $2.09M | $1.93M | $1.96M |
| Current assets | $2.58M | $2.58M | $2.17M | $7.35M | $2.70M | $1.93M | $1.64M | $1.54M |
| Cash and equivalents | $1.66M | $1.66M | $1.10M | $5.81M | $1.66M | $918.26K | $723.48K | $496.85K |
| Total liabilities | $5.04M | $5.04M | $4.02M | $2.19M | $3.06M | $8.15M | $3.84M | $1.64M |
| Short-term debt | $3.62M | $3.62M | $2.55M | $500.00K | $500.00K | $1.63M | $487.83K | $444.11K |
| Long-term debt | N/A | N/A | $0 | N/A | $500.00K | $4.44M | $2.50M | $300.00K |
| Shareholder equity | $226.06K | $226.06K | $205.17K | $7.32M | $230.56K | -$6.06M | -$1.91M | $315.55K |
Quarterly
| Line item | Jul 2026 | Jun 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.74M | $5.26M | $5.26M | $7.55M | $6.00M | $6.44M | $4.22M | $5.70M | $6.00M | $6.44M | $9.50M | $10.80M |
| Total liabilities | $5.77M | $5.04M | $5.04M | $4.90M | $1.81M | $3.30M | $4.02M | $3.92M | $1.81M | $3.30M | $2.19M | $2.17M |
| Cash and equivalents | $29.91K | $1.66M | $1.66M | $3.40M | $1.95M | $2.79M | $1.10M | $2.60M | $1.95M | $2.79M | $5.81M | $7.08M |
| Shareholder equity | -$2.03M | $226.06K | $226.06K | $2.65M | $4.18M | $3.14M | $205.17K | $1.79M | $4.18M | $3.14M | $7.32M | $8.63M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Apr 2026.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.43M | -$7.41M | -$6.07M | -$5.77M | -$3.64M | -$2.45M | -$3.84M |
| Capital expenditures | $3.55K | $3.16K | $64.45K | $18.31K | $1.93K | $712 | $11.42K |
| Free cash flow | -$7.43M | -$7.42M | -$6.13M | -$5.79M | -$3.65M | -$2.45M | -$3.85M |
| Investing cash flow | -$44.45K | -$30.19K | -$125.27K | -$18.31K | -$1.93K | -$712 | $8.17K |
| Financing cash flow | $8.03M | $2.73M | $10.34M | $6.53M | $3.84M | $2.68M | $1.81M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.32M | -$1.68M | -$1.46M | -$2.33M | -$1.95M | -$1.59M | -$1.62M | -$2.18M | -$2.02M | -$1.58M | -$2.10M | -$988.19K |
| Capital expenditures | $274.50K | $19.03M | $9.48M | $13.03K | $0 | $7.81K | $15.70K | $5.84K | $833 | $48.80K | $8.79K | $1.95K |
| Free cash flow | -$1.59M | -$20.71M | -$10.94M | -$2.35M | -$1.95M | -$1.60M | -$1.64M | -$2.19M | -$2.02M | -$1.63M | -$2.11M | -$990.14K |
Frequently Asked Questions About HSCS
What is HeartSciences' annual revenue?
HeartSciences reported revenue of $4.32K for the fiscal year ended Apr 30, 2026.
How fast is HeartSciences' revenue growing?
Revenue was down 0.7% for the fiscal year ended Apr 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -5.7%.
Is HeartSciences profitable?
No. HeartSciences reported net income of -$9.14M for the fiscal year ended Apr 30, 2026, with a net margin of -211666.5%.
How much free cash flow does HSCS generate?
For the fiscal year ended Apr 30, 2026, operating cash flow of -$7.43M minus capital expenditures of $3.55K produced free cash flow of -$7.43M.
How much debt does HeartSciences have?
The balance sheet dated Jun 30, 2026 reported short-term debt of $3.62M and cash and equivalents of $1.66M.
HSCS pages: Overview, Earnings, Forecast, Financials, Competitors